ULURU INC. PRESENTS RESULTS OF FIRST RANDOMIZED CLINICAL TRIAL FOR ALTRAZEAL™ AT THE SYMPOSIUM ON ADVANCED WOUND CARE (SAWC) FALL MEETING IN WASHINGTON D.C.

09/16/2009

Addison, Texas, September 16, 2009; ULURU Inc. (NYSE Alternext: ULU) announced today the presentation of results from the first completed randomized clinical trial for Altrazeal at the SAWC Fall symposium in Washington D.C. September 16-18. The recently completed clinical study compared healing, pain and comfort of skin graft donor sites treated with either Altrazeal™ or with a leading commercial sodium carboxymethylcellulose-silver ("CMC-Ag") dressing. Read More